US2009156671A1PendingUtilityA1
Deuterium-enriched oxybutynin
Est. expiryJun 1, 2027(~0.9 yrs left)· nominal 20-yr term from priority
Inventors:Anthony W. Czarnik
A61P 13/10A61K 31/21
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present application describes deuterium-enriched oxybutynin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
Claims
exact text as granted — not AI-modified1 . A method for treating overactive bladder comprising: administering, to a patient in need thereof, a therapeutically effective amount of a deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 31 are independently selected from H and D; and the abundance of deuterium in R 1 -R 31 is at least 3% provided that the compound is other than:
(a) a compound where each of R 22 -R 31 is D or
(b) a compound where each of R 20 -R 21 is D.
2 . The method of claim 1 , wherein the abundance of deuterium in R 1 -R 31 is selected from at least 3%, at least 6%, at least 13%, at least 19%, at least 26%, at least 32%, at least 39%, at least 45%, at least 52%, at least 58%, at least 65%, at least 71%, at least 77%, at least 84%, at least 90%, at least 97%, and 100%.
3 . The method of claim 1 , wherein the abundance of deuterium in R 1 is 100%.
4 . The method of claim 1 , wherein the abundance of deuterium in R 1 , R 20 -R 21 , and R 22 -R 31 is selected from at least 8%, at least 15%, at least 23%, at least 31%, at least 38%, at least 46%, at least 54%, at least 62%, at least 69%, at least 77%, at least 85%, at least 92%, and 100%.
5 . The method of claim 1 , wherein the abundance of deuterium in R 20 -R 21 and R 22 -R 31 is selected from at least 8%, at least 17%, at least 25%, at least 33%, at least 42%, at least 50%, at least 58%, at least 67%, at least 75%, at least 83%, at least 92%, and 100%.
6 . The method of claim 1 , wherein the abundance of deuterium in R 2 -R 6 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.
7 . The method of claim 1 , wherein the abundance of deuterium in R 7 -R 17 is selected from at least 9%, at least 18%, at least 27%, at least 36%, at least 45%, at least 56%, at least 64%, at least 73%, at least 82%, at least 91%, and 100%.
8 . The method of claim 1 , wherein the compound is selected from compounds 1-8 of Table 1:
9 . The method of claim 1 , wherein the compound is selected from compounds 9-16 of Table 2:
10 . A method for treating overactive bladder comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 31 are independently selected from H and D; and the abundance of deuterium in R 1 -R 31 is at least 3% provided that the compound is other than:
(a) a compound where each of R 22 -R 31 is D or
(b) a compound where each of R 20 -R 21 is D.
11 . The method of claim 10 , wherein the abundance of deuterium in R 1 -R 31 is selected from at least 3%, at least 6%, at least 13%, at least 19%, at least 26%, at least 32%, at least 39%, at least 45%, at least 52%, at least 58%, at least 65%, at least 71%, at least 77%, at least 84%, at least 90%, at least 97%, and 100%.
12 . The method of claim 10 , wherein the abundance of deuterium in R 1 is 100%.
13 . The method claim 10 , wherein the abundance of deuterium in R 1 , R 20 -R 21 , and R 22 -R 31 is selected from at least 8%, at least 15%, at least 23%, at least 31%, at least 38%, at least 46%, at least 54%, at least 62%, at least 69%, at least 77%, at least 85%, at least 92%, and 100%.
14 . The method of claim 10 , wherein the abundance of deuterium in R 20 -R 21 and R 22 -R 31 is selected from at least 8%, at least 17%, at least 25%, at least 33%, at least 42%, at least 50%, at least 58%, at least 67%, at least 75%, at least 83%, at least 92%, and 100%.
15 . The method of claim 10 , wherein the abundance of deuterium in R 2 -R 6 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.
16 . The method of claim 10 , wherein the abundance of deuterium in R 7 -R 17 is selected from at least 9%, at least 18%, at least 27%, at least 36%, at least 45%, at least 56%, at least 64%, at least 73%, at least 82%, at least 91%, and 100%.
17 . The method of claim 10 , wherein the compound is selected from compounds 1-8 of Table 1:
18 . The method of claim 10 , wherein the compound is selected from compounds 9-16 of Table 2:
19 . A method for treating overactive bladder comprising: administering, to a patient in need thereof, a therapeutically effective amount of a mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 31 are independently selected from H and D; and the abundance of deuterium in R 1 -R 31 is at least 3% provided that the compound is other than:
(a) a compound where each of R 22 -R 31 is D or
(b) a compound where each of R 20 -R 21 is D.
20 . The method of claim 19 , wherein the abundance of deuterium in R 1 -R 31 is selected from at least 3%, at least 6%, at least 13%, at least 19%, at least 26%, at least 32%, at least 39%, at least 45%, at least 52%, at least 58%, at least 65%, at least 71%, at least 77%, at least 84%, at least 90%, at least 97%, and 100%.
21 . The method of claim 19 , wherein the abundance of deuterium in R 1 is 100%.
22 . The method of claim 19 , wherein the abundance of deuterium in R 1 , R 20 -R 21 , and R 22 -R 31 is selected from at least 8%, at least 15%, at least 23%, at least 31%, at least 38%, at least 46%, at least 54%, at least 62%, at least 69%, at least 77%, at least 85%, at least 92%, and 100%.
23 . The method of claim 19 , wherein the abundance of deuterium in R 20 -R 21 and R 22 -R 31 is selected from at least 8%, at least 17%, at least 25%, at least 33%, at least 42%, at least 50%, at least 58%, at least 67%, at least 75%, at least 83%, at least 92%, and 100%.
24 . The method of claim 19 , wherein the abundance of deuterium in R 2 -R 6 is selected from at least 20%, at least 40%, at least 60%, at least 80%, and 100%.
25 . The method of claim 19 , wherein the abundance of deuterium in R 7 -R 17 is selected from at least 9%, at least 18%, at least 27%, at least 36%, at least 45%, at least 56%, at least 64%, at least 73%, at least 82%, at least 91%, and 100%.
26 . The method of claim 19 , wherein the compounds are selected from compounds I-8 of Table 1:
27 . The method of claim 19 , wherein the compounds are selected from compounds 9-16 of Table 2:Join the waitlist — get patent alerts
Track US2009156671A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.